Nestle Targets Millions of GLP 1 Users with AI Products to Counter Weight Loss Drug Threat

The company is integrating nutritional science and AI to design new foods for consumers taking GLP 1 medications like Wegovy and Ozempic. This strategy serves a market of millions of drug users to mitigate potential declines in food consumption associated with appetite suppression.

Nestle is seeking to convert the rise of these medicines from a demand threat into a growth opportunity by building a specialized product ecosystem. The initiative uses data and nutritional research to create products tailored to the physiological requirements of patients on weight loss therapies.